Subscribe
canada-beefeaters
17 September 2013Americas

Eli Lilly sues Canadian government for “unfair” patent rulings

Eli Lilly has filed a Notice of Arbitration (NOA) against the Canadian government, alleging recent decisions that invalidated patents covering its Zyprexa and Strattera drugs were in breach of the North American Free Trade Agreement (NAFTA).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Canada responds to Lilly’s NAFTA complaint
15 July 2014   The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Canada responds to Lilly’s NAFTA complaint
15 July 2014   The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.

More on this story

Americas
Canada responds to Lilly’s NAFTA complaint
15 July 2014   The Canadian government has responded to Eli Lilly’s complaint that recent decisions to invalidate two Lilly patents violated the North American Free Trade Agreement, saying that Lilly’s challenge is “wholly without merit”, and should be dismissed.

More features

Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda
EOFlow ordered to pay rival $452m over insulin patch trade secrets
Amgen faces pushback over bid to narrow patent scope